CBIO.US Crescent Biopharma, Inc.

Healthcare Biotechnology USA Stocks
14.15 USD
Close of Nov 14, 2026
8.72 27.41
Market cap
USD 526M
P/E
-
P/B
3.36x
ROE
-40.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CBIO.US undervalued?

Graham number

The Graham number of Crescent Biopharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Crescent Biopharma, Inc. fundamental analysis

No fundamental analysis for Crescent Biopharma, Inc. yet.

Crescent Biopharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly k…

Full company profile